

PRODUCT DESCRIPTION:

NATtrol™ Respiratory Pathogen Panel-1* (qualitative) is formulated with purified, intact viral particles and bacterial cells that have been chemically modified to render them non-infectious and refrigerator stable. NATRPP-1 contains a total of 6 x 0.25mL vials: 5 vials of the viral/bacterial NATtrol™ targets (1 vial of each pool) and 1 vial of negative (matrix only) as listed in Table 1. The panel members are supplied in a propriety matrix.

*Pat.:http://www.zeptometrix.com/patent-information/

INTENDED USE:

 NATtrol™ RPP-1 Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence of viral and bacterial nucleic acids (from organisms listed in Table 1).
 NATRPP-1 can also be used for validation of clinical assays, development of diagnostic tests and training of laboratory personnel.

WARNINGS AND PRECAUTIONS:

- NATtrol™ inactivation was carried out on microorganism stocks used to formulate the panel members. The inactivation was verified in a standard microbiological growth protocol.
- This panel contains inactivated microorganisms and materials of human and animal origin. Safe practices suggest that the controls be considered potentially infectious and to use Universal Precautions when handling.
- Refer to CDC guidelines and local regulations for handling and disposal.
- The matrix used in the manufacture of this product is treated with 0.09% sodium azide. It was manufactured from Human Serum Albumin that have been tested and found to be non-reactive at the donor level for HIV-1/HIV-2 Antibody, HBsAg and HCV Antibody by FDA licensed donor screening test methods. All materials are also tested for HIV-1 and HCV by FDA approved Nucleic Acid Test (NAT) methods.
- Heat inactivated Fetal Bovine Serum used in the manufacture of
 this product meet applicable USDA requirements for abattoir
 sourced animals, traceability and country of origin. The materials
 were collected at USDA licensed establishments or legally
 imported from countries recognized by the USDA as negligible or
 controlled for risk for Bovine Spongiform Encephalopathy (BSE)
 and other exotic disease agents. Donor animals were inspected
 ante and post mortem at the abattoir as required by the USDA.
- Do not use past the expiration date on the label.
- To avoid cross-contamination, use separate pipette tips for all materials.

RECOMMENDED STORAGE:

 NATtrol™ Respiratory Pathogen Panel-1 should be stored at 2-8°C.

INSTRUCTIONS FOR USE:

- Mix vial vigorously for at least 5 secs.
- Process according to manufacturer's instructions for sample to result assays
- Extract nucleic acid prior to use in downstream assays that are not sample to result.

LIMITATION:

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES
- Quality control materials should be used in accordance with local, state, federal, and accreditation requirements.
- This product is not intended to replace the manufacturer's controls provided with the assay.

EXPECTED RESULTS:

- Each laboratory must evaluate the product and establish their own acceptance criteria.
- The table shown below is for informational purposes only.

TABLE 1: PANEL MEMBERS

Panel Member (Strain) 1 2 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	-	Negative
(A/NY/02/09) Parainfluenza Type 4A Parainfluenza Type 4B Rhinovirus (1A) Adenovirus Type 3 Influenza A H1 (A/New Caledonia/20/99) Respiratory Syncytial Virus A Parainfluenza Type 1 Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Parainfluenza Type 4B Rhinovirus (1A) Adenovirus Type 3 Influenza A H1 (A/New Caledonia/20/99) Respiratory Syncytial Virus A Parainfluenza Type 1 Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
AB Rhinovirus (1A) Adenovirus Type 3 Influenza A H1 (A/New Caledonia/20/99) Respiratory Syncytial Virus A Parainfluenza Type 1 Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Adenovirus Type 3 Influenza A H1 (A/New Caledonia/20/99) Respiratory Syncytial Virus A Parainfluenza Type 1 Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Influenza A H1 (A/New Caledonia/20/99) Respiratory Syncytial Virus A Parainfluenza Type 1 Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		_
Respiratory Syncytial Virus A Parainfluenza Type 1 Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus OC43 Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Parainfluenza Type 1 Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus OC43 Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Coronavirus NL63 Mycoplasma pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus OC43 Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
pneumoniae (M129) Influenza A H3 (A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus OC43 Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
(A/Brisbane/10/07) Respiratory Syncytial Virus B (CH93(18)-18) Coronavirus OC43 Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Syncytial Virus B (CH93(18)-18) Coronavirus OC43 Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Coronavirus HKU-1 (Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
(Recombinant) Influenza B (B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
(B/Florida/02/06) Parainfluenza Type 3 Human Metapneumovirus (Peru6-2003)** Legionella		
Human Metapneumovirus (Peru6-2003)** Legionella		
Metapneumovirus (Peru6-2003)** Legionella	′	
	,	
pneumophila (Philadelphia)	<i>,</i>	
Parainfluenza Type 2	✓	
Coronavirus 229E	✓	
Human Bocavirus	✓	
Chlamydophila pneumoniae (CWL-029)		
Negative	✓	✓

^{**}This product is sold by Zeptometrix under license from Vironovative B. V under patent applications, including U.S. Patent Applications 10/371,099 and 10/371,12 and any patents that issue from applications related to PCT/NL02/00040 and PCT/US03/05271.

PINATRPP-1 Revision: 09

Effective Date: 11/01/2021

REF	Catalog Number	X	Temperature Limitation
LOT	Batch Code	M	Expiration Date
RUO	For Research Use Only	®	Biological Risk
4	Manufacturer		